{"name":"Histogenics Corporation","slug":"histogenics-corporation","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxObmFEREt0UlBoU2NCa2VkOEpVcWdnZEFSbU05TkxJeE9LeEFsaVNkMDZsX0hwYk0wWlRIS2Vtc19kVXFPajh6dE92VjFuRy1TTkJubTRGcEFjT1NXSFlOUG1fS1FWWS1uR0lCR1J4MTZROVY4U00zeVQ3a25KdURwXzEzOVgtZTUtODRKMnZ1VGQzdlU?oc=5","date":"2022-12-16","type":"regulatory","source":"BioSpace","summary":"NeoCart’s Revival Continues as FDA Approves Ocugen’s Phase III Trial Design (Updated) - BioSpace","headline":"NeoCart’s Revival Continues as FDA Approves Ocugen’s Phase III Trial Design (Updated)","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxPa0dpSVRRdVlZMzVKZnRjSGt5SGR6UmFZNl9TOG9OaGNsaUQxZlBJdmh0Q1B4MzdpcjdncHF2X0FvRzk3V3lXS0ZNYmR6dTlFWmNVUUxBSXhSZEJGczFyMnJRT0EtWlpROFA3aTNhQVREbE9Ka096dUZlbHFsUzJ1cWpEeDZ4T3ZrblVCYUFQdEhNUUVaRnFQRVVwczVMdGRyMEE?oc=5","date":"2022-08-24","type":"pipeline","source":"citybiz","summary":"ValenzaBio Appoints Peter Greenleaf to its Board of Directors - citybiz","headline":"ValenzaBio Appoints Peter Greenleaf to its Board of Directors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxNRUpLX0lpa09LRUhkMk9NNW11azBLazljdXNFS2pKOVppTFVjZ3pvTFN5WU5OYmRMdmhLSWZySmE2dmZ2RTIxM180d2RWRjhjREZKbFhjR2UzLU1abDV0MVlQOG5JeGtndHRLdER2RlNSb3dtTUlaRHdnSDNySDNjcUIyTV83amg2eUtqSXFJTkVNMUVuUVA5NjkyQnpEdWo2M3gzZDdsVVFKRFl1c3l4YURiQ1pqdzlQbU5VUklR?oc=5","date":"2019-04-08","type":"deal","source":"Ocugen, Inc.","summary":"Histogenics and Ocugen Enter into Definitive Merger Agreement to Create Nasdaq-Listed Clinical-Stage Company Developing Novel Ocular Gene Therapies and Biotherapeutics - Ocugen, Inc.","headline":"Histogenics and Ocugen Enter into Definitive Merger Agreement to Create Nasdaq-Listed Clinical-Stage Company Developing ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxOYzhYcnkxWkVnNXRUbU5FZTFtbnhfNWFwVzJpbUJWeHAyZjV3SzViZ1lKN0xxYUJ0YlA0VmNzWkNlOFZHRElFa2xnRVFhT2owdGZQSlF2S0tJNUFFZ0dIT2dUQk5JdjBWeF9kVWNQVF9kOFVwa2otdS1Db2xEV3A5QnNwOGp5M2JwMTM2dDhn?oc=5","date":"2019-04-08","type":"pipeline","source":"pharmaphorum","summary":"Ocugen, Histogenics merge to form eye disease specialist - pharmaphorum","headline":"Ocugen, Histogenics merge to form eye disease specialist","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwJBVV95cUxNTk52Rnl4bWc2WVM2SjR0dW1CY3VhNGVjUThVUzJfRTNxbHBySGItTFVaOHlkNWlJaFBqSE9DQmtNMXNZQWRLNlhHZDdabkpTSl9PVmZBNjZDeG9zMG9qa2FCRnFiRVRYOUxUa3JYenpZN1lpamdIamo3UjNoNF9uWEV0emFKZ1loUi00Q3pzRFVyVFNrMnQxUU1wclNVbGU5SWN6RjNLd3E5Z09FNUFwSjR4SkVpMk4zeElzRHZVM3RNN1ljMTY0cE51SUV1SVYxaFROemJhMnUyblpPT3VMcEl4ZDZKRXp2bjliYjZ4S3lVb00tNjVxaUNJbVlwXy1uSG10M0NjdUloZ28?oc=5","date":"2018-09-05","type":"trial","source":"Proactive financial news","summary":"Histogenics shares lose nearly three-fourths of their value after Phase 3 trial on knee damage treatment fails - Proactive financial news","headline":"Histogenics shares lose nearly three-fourths of their value after Phase 3 trial on knee damage treatment fails","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxPcU1nSEI4eVlOSXZBcUNERmhmaTlTZXV2VTY2b2dlT2dZcUx3VkJiR3BqR29jSzRGWHFobXhzVHB0cUhHMU9rVnE0OWxzSHA5RG81M0liYjE0ZGJ1NkJkQ3R1ZVJ1THkyYVRVbTRkOXNhRi1EdlEyZ19JdTAtQ0JJWUNUTld2eUZ6ZGRyZkZlSHpUVWtQOTBkWTltUWEtNC12YzBDMDZ5UUIxQ1NuZFVGTlVoZw?oc=5","date":"2017-07-18","type":"deal","source":"Insider Monkey","summary":"13G Filing: Partner Fund Management and Aerie Pharmaceuticals Inc (AERI) - Insider Monkey","headline":"13G Filing: Partner Fund Management and Aerie Pharmaceuticals Inc (AERI)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxQWG1GdXFXcElUdkMxN0tTeG5xRjB5amI5dVdWRGNHdEJWdXpyZ2xiUGItVElicDlSWW9tLTNCVjJqbGJNTWVYQW9TTU5ZSDBDRUdKZVc0Uzk2QmI0Nk9VZVlHTVl2c2JuQ1J6akJrM042bDkzWENuRmdNM2hlaGgtanJoWFF6T1JSaDdlRHgzcmJHaDBZQVhDX0RFU3hLbDc2OGlFdkVJU2NsX0xqTmVwNUdidkZVbG9kVjlsd2ZVbEg1LXcyOVhV?oc=5","date":"2017-06-28","type":"trial","source":"BioSpace","summary":"Histogenics Completes Enrollment For Phase III Clinical Trial Of Neocart To Treat Knee Cartilage Damage - BioSpace","headline":"Histogenics Completes Enrollment For Phase III Clinical Trial Of Neocart To Treat Knee Cartilage Damage","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxQTWFBOXRIdW03aHRFWEgyUHRFc2dyaWtpTWt0azljM0VTUXBpTTBRTTBub0ZncjAxSGRoLVRSRzZzdWNkNkhjd0NMS1J6RzBJaTlpYWpwTEVRRkh6dFdNRTJId3F4ZmR1aW95RkNTUWZ2MkVCVzYxd19JQmhDb3FvRjNhUjdoSnVHUHBuX0RDUWZRVTd3X2doQ1VNbGdsWnM?oc=5","date":"2013-06-12","type":"pipeline","source":"PMLiVE","summary":"Histogenics names former MedImmune president as CEO - PMLiVE","headline":"Histogenics names former MedImmune president as CEO","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}